174 related articles for article (PubMed ID: 34396857)
1. Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure.
Vergaro G; Aimo A; Campora A; Castiglione V; Prontera C; Masotti S; Musetti V; Chianca M; Valleggi A; Spini V; Emdin M; Passino C
Amyloid; 2021 Dec; 28(4):252-258. PubMed ID: 34396857
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of soluble ST2 in AL and TTR cardiac amyloidosis: a multicenter study.
Nicol M; Vergaro G; Damy T; Kharoubi M; Baudet M; Canuti ES; Aimo A; Castiglione V; Emdin M; Royer B; Harel S; Cohen-Solal A; Arnulf B; Logeart D
Front Cardiovasc Med; 2023; 10():1179968. PubMed ID: 37600055
[TBL] [Abstract][Full Text] [Related]
3. Prognosis of Light Chain Amyloidosis With Preserved LVEF: Added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System.
Barros-Gomes S; Williams B; Nhola LF; Grogan M; Maalouf JF; Dispenzieri A; Pellikka PA; Villarraga HR
JACC Cardiovasc Imaging; 2017 Apr; 10(4):398-407. PubMed ID: 27639764
[TBL] [Abstract][Full Text] [Related]
4. [Cardiac amyloidosis: pathological classification and clinical analysis of 48 cases].
Yu TP; Hou J; Yang TJ; Lei S; Yang M; Su YY; Chen YC; Wu Y; Chen XQ
Zhonghua Bing Li Xue Za Zhi; 2023 Jul; 52(7):671-677. PubMed ID: 37408396
[No Abstract] [Full Text] [Related]
5. Identification of prognostic markers in transthyretin and AL cardiac amyloidosis.
Damy T; Jaccard A; Guellich A; Lavergne D; Galat A; Deux JF; Hittinger L; Dupuis J; Frenkel V; Rigaud C; Plante-Bordeneuve V; Bodez D; Mohty D
Amyloid; 2016 Sep; 23(3):194-202. PubMed ID: 27647161
[TBL] [Abstract][Full Text] [Related]
6. Effects of ivabradine therapy on heart failure biomarkers.
Ordu S; Yildiz BS; Alihanoglu YI; Ozsoy A; Tosun M; Evrengul H; Kaftan HA; Ozhan H
Cardiol J; 2015; 22(5):501-9. PubMed ID: 25733317
[TBL] [Abstract][Full Text] [Related]
7. [Predictive value of N-terminal B-type natriuretic peptide on outcome of elderly hospitalized non-heart failure patients].
Li YY; Liang YD; Yao SM; Zheng PP; Zeng XZ; Cui LL; Guo D; Wang H; Yang JF
Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Aug; 48(8):661-668. PubMed ID: 32847322
[No Abstract] [Full Text] [Related]
8. Multimarker Strategy for Heart Failure Prognostication. Value of Neurohormonal Biomarkers: Neprilysin vs NT-proBNP.
Bayes-Genis A; Barallat J; Galán A; de Antonio M; Domingo M; Zamora E; Gastelurrutia P; Vila J; Peñafiel J; Gálvez-Montón C; Lupón J
Rev Esp Cardiol (Engl Ed); 2015 Dec; 68(12):1075-84. PubMed ID: 26297179
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of sST2 and NT-proBNP at admission in heart failure with preserved, mid-ranged and reduced ejection fraction.
Huang A; Qi X; Hou W; Qi Y; Zhao N; Liu K
Acta Cardiol; 2018 Feb; 73(1):41-48. PubMed ID: 28944719
[TBL] [Abstract][Full Text] [Related]
10. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis.
Nicol M; Deney A; Lairez O; Vergaro G; Emdin M; Carecci A; Inamo J; Montfort A; Neviere R; Damy T; Harel S; Royer B; Baudet M; Cohen-Solal A; Arnulf B; Logeart D
Eur J Heart Fail; 2021 Feb; 23(2):231-239. PubMed ID: 33006180
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of plasma renin activity in heart failure.
Vergaro G; Emdin M; Iervasi A; Zyw L; Gabutti A; Poletti R; Mammini C; Giannoni A; Fontana M; Passino C
Am J Cardiol; 2011 Jul; 108(2):246-51. PubMed ID: 21545993
[TBL] [Abstract][Full Text] [Related]
13. Low QRS Voltages in Cardiac Amyloidosis: Clinical Correlates and Prognostic Value.
Cipriani A; De Michieli L; Porcari A; Licchelli L; Sinigiani G; Tini G; Zampieri M; Sessarego E; Argirò A; Fumagalli C; De Gaspari M; Licordari R; Russo D; Di Bella G; Perfetto F; Autore C; Musumeci B; Canepa M; Merlo M; Sinagra G; Gregori D; Iliceto S; Perazzolo Marra M; Cappelli F; Rapezzi C
JACC CardioOncol; 2022 Nov; 4(4):458-470. PubMed ID: 36444225
[TBL] [Abstract][Full Text] [Related]
14. Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T.
Aimo A; Januzzi JL; Vergaro G; Richards AM; Lam CSP; Latini R; Anand IS; Cohn JN; Ueland T; Gullestad L; Aukrust P; Brunner-La Rocca HP; Bayes-Genis A; Lupón J; de Boer RA; Takeishi Y; Egstrup M; Gustafsson I; Gaggin HK; Eggers KM; Huber K; Gamble GD; Ling LH; Leong KTG; Yeo PSD; Ong HY; Jaufeerally F; Ng TP; Troughton R; Doughty RN; Passino C; Emdin M
Eur J Heart Fail; 2020 Nov; 22(11):2078-2088. PubMed ID: 31919929
[TBL] [Abstract][Full Text] [Related]
15. N-terminal pro-B-type natriuretic peptide in chronic heart failure: The impact of sex across the ejection fraction spectrum.
Faxén UL; Lund LH; Orsini N; Strömberg A; Andersson DC; Linde C; Dahlström U; Savarese G
Int J Cardiol; 2019 Jul; 287():66-72. PubMed ID: 31005415
[TBL] [Abstract][Full Text] [Related]
16. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
[TBL] [Abstract][Full Text] [Related]
17. Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms.
Gonzalez-Lopez E; Escobar-Lopez L; Obici L; Saturi G; Bezard M; Saith SE; AbouEzzeddine OF; Mussinelli R; Gagliardi C; Kharoubi M; Griffin JM; Dispenzieri A; Vilches S; Perlini S; Longhi S; Oghina S; Rivas A; Grogan M; Maurer MS; Damy T; Palladini G; Rapezzi C; Garcia-Pavia P
JACC CardioOncol; 2022 Nov; 4(4):442-454. PubMed ID: 36444226
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial.
Butt JH; Adamson C; Docherty KF; de Boer RA; Petrie MC; Inzucchi SE; Kosiborod MN; Maria Langkilde A; Lindholm D; Martinez FA; Bengtsson O; Schou M; O'Meara E; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Jhund PS; McMurray JJV; Køber L
Circ Heart Fail; 2021 Dec; 14(12):e008837. PubMed ID: 34802253
[TBL] [Abstract][Full Text] [Related]
19. Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis - Report from the Transthyretin Amyloidosis Outcome Survey (THAOS).
Kristen AV; Maurer MS; Rapezzi C; Mundayat R; Suhr OB; Damy T;
PLoS One; 2017; 12(4):e0173086. PubMed ID: 28384285
[TBL] [Abstract][Full Text] [Related]
20. [Prognostic value of N-terminal B-type natriuretic peptide on all-cause mortality in heart failure patients with preserved ejection fraction].
Cao J; Jin XJ; Zhou J; Chen ZY; Xu DL; Yang XC; Dong W; Li LW; Luo J; Chen L; Fu M; Zhou JM; Ge JB
Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):875-881. PubMed ID: 31744276
[No Abstract] [Full Text] [Related]
[Next] [New Search]
